- Open Access
Phenotypic analysis of peripheral B cell populations during Mycobacterium tuberculosis infection and disease
© The Author(s). 2016
- Received: 26 May 2016
- Accepted: 22 July 2016
- Published: 29 July 2016
Mycobacterium tuberculosis (Mtb) remains an unresolved threat resulting in great annual loss of life. The role of B cells during the protective immunity to Mtb is still unclear. B cells have been described as effector cells in addition to their role as antibody producing cells during disease.
Here we aim to identify and characterize the frequency of peripheral B-cell subpopulations during active Tuberculosis and over treatment response. Analysis were done for both class switched (CS) and non-class switched (NCS) phenotypes.
We recruited participants with active untreated pulmonary Tuberculosis, other lung diseases and healthy community controls. All groups were followed up for one week from recruitment and the TB cases till the end of treatment (month 6).
Peripheral blood samples were collected, stained with monoclonal antibodies to CD19+ cells, Immunoglobulin (Ig) M, plasma cells (CD 138+), marker of memory (CD27+), immune activation (CD23+) and acquired on a flow cytometer. Circulating Marginal zone B cells (CD19+IgM+CD23−CD27+) and memory phenotypes are able to distinguish between TB diagnosis and end of treatment. The frequency of mature B cells from TB cases are lower than that of other-lung diseases at diagnosis. A subpopulation of activated memory B cells (CD19+IgM+CD23+CD27+) cells are present at the end of TB treatment.
This study identified distinctive B cell subpopulations present during active TB disease and other lung disease conditions. These cell populations warrants further examination in larger studies as it may be informative as cell markers or as effectors/regulators in TB disease or TB treatment response.
- B cells
- Marginal zone
- Plasma cells
- Immune activation
Tuberculosis (TB), remains an unresolved threat that is responsible for great mortality and morbidity in humans. Its causative agent, Mycobacterium tuberculosis (Mtb), was ultimately responsible for 9 million newly reported cases and 1.5 million deaths during 2013 . Although great progress has been made on T cell based tuberculosis research, it is imperative that new avenues have to be explored and that previously underappreciated cell types are re-evaluated for their roles during the tuberculosis infection with the expectation of bringing an end to the epidemic. It is commonly accepted that B cell and antibody-mediated responses confers protection against extracellular pathogens and that the regulation and control of intracellular organisms are through cellular immune mechanisms.
There is increasing evidence that demonstrate B cells functioning as mediators (in both effector and regulatory roles) of immunity outside of their classically designated profession as the facilitators of humoral immunity. B cell activation by Toll-like receptor (TLR) antigens or whole organisms (like BCG or Mtb) can lead to a range of outcomes to the host, either by producing antibody, secreting cytokines (including interleukin (IL)-6, IL-10, and interferon (IFN)-gamma) or presenting antigen to naïve T cells [2–5]. B cell responses are beneficial to the host during infections and damaging during autoimmune disease. Conversely, B cells have the capacity to limit the hosts defence (inflammatory response) against pathogens and shield against autoimmune pathologies. This demonstrates that B cells can have distinct roles as drivers and regulators of immunity depending on the functional properties they gain following receptor activation and differentiation.
Although ongoing studies and literature supports the functional role of B cells during TB , the respective change in the frequency of the circulating B cell repertoire during active Mtb infection remains a topic for discussion as some studies report either a significant decrease  or increase  of peripheral blood B cell populations in actively infected patients.
Immuno-phenotyping has proven to be a very useful tool in the identification, monitoring and management of various clinical diseases [9–11]. Although recent publications have sought to develop in depth multicolour flow cytometric panels for the accurate delineation of various lymphocyte populations and subpopulations (including B cells) during immunodeficiencies [12, 13], very few studies exist that specifically assess immune-phenotypic change during active Mycobacterium tuberculosis infection [7, 14]. Little is known about the immune-phenotypic change of the B cell lineage during active Mtb as current literature largely focuses on the general B cell presence (primarily looking at CD19+ B cells only) [7, 14], rather than on an in-depth analysis of various populations and subpopulations. This results in a lack of knowledge pertaining to changes in B cell populations implicated in effector roles such as circulating memory B cells or plasma populations. It also does not elucidate the current activation state of B cells nor the expression of surface molecules, thus highlighting the need for further investigation regarding this matter.
In this brief preliminary report, a total of 96 participant samples spanning three groups (tuberculosis – active infection; 52 samples, other-lung disease; 24 samples, and healthy community controls; 20 samples) and various time points relating to treatment were used to assess the B cell repertoire in detail with the hope of identifying unique phenotypic differences between the groups that could suffice as biomarkers of disease. The primary contribution of this data would be to map the phenotypic distribution of B cells between these groups with a vast range, as it would include phenotypes for both IgM+ and IgM− B cells. The actual isotype linked to the IgM− phenotypes have not been determined for this study.
Clinical and demographic data of the study participants
Gender-ratio (Male: Female)
Other-lung Disease Diagnosisa
Tuberculosis (n = 52)
3 M : 1 F
17.8 ± 1.7
HC (n = 20)
4 M : 1 F
22.9 ± 6.3
OLD (n = 24)
1 M : 1 F
27.4 ± 8.2
Pneumonia (n = 10)
Asthma (n = 2)
COPD (n = 1)
Pleural Effusion, Reactive (n = 1)
B cell phenotyping
Differences in the frequency of B cell subsets between the groups were analysed using the non-parametric analysis with a Mann-Whitney correction and performed by Dr Justin Harvey (Stellenbosch University). All analysis were performed with the Statistica 12 software (Statsoft, Ohio, USA).
Circulating marginal zone B cells and memory phenotypes distinguish between TB diagnosis and end of treatment
Circulating marginal zone- and Mature B cells can distinguish TB from other-lung diseases at diagnosis
In the attempt to identify phenotypes that were unique to tuberculosis when compared to other-lung based diseases, two results showed to be significant. The first was NCS marginal zone (MZ) B cells (CD19+IgM+CD27+CD23−) with p = 0.02092 and secondly CS mature B cells were significant with p = 0.00026 (Fig. 4). With both of these phenotypes significantly lower in peripheral circulation during active TB disease (especially the CS mature B cells), it raises the question whether TB actively suppresses the B cell repertoire during disease. The NCS mature B cell repertoire does not recover to baseline levels during the first week of treatment as one would expect (in line with chemotherapeutic treatment alleviating bacterial burden). These findings support the notion that there is a possible underlying mechanism exploited by Mtb that could be crucial to the management of the infection as both MZ and mature B cells are implicated in effector functions of the adaptive immune system, as seen with the overexpression of programmed death 1 (PD-1) on lymphocyte frequencies during active TB infection .
Class switched and non-class switched mature B cells distinguish between tuberculosis, other-lung based diseases and healthy controls
This pilot study identified unique variations in the B cell repertoire during active tuberculosis infection when compared to healthy controls, other-lung based diseases and over the course of TB treatment. The first observation of memory-based phenotypes being the major distinguishers between diagnosis and end of treatment in both class switched and non-class switched phenotypes holds promise as markers for treatment response. The second important finding of this study is that circulating marginal zone B cells could not only distinguish between TB diagnosis and the end of treatment, but also has significantly different frequencies when compared to other-lung based diseases making it a candidate as biomarker for not only treatment response, but distinguishing active TB disease from other-lung based diseases. The observation that NCS and CS mature B cells could best distinguish between TB and the two control groups (healthy controls and other lung diseases) at diagnosis, but that their respective peripheral frequencies are present at an inverse level. Taken together, these results show that mainly B cell phenotypes implicated in activation and subsequent effector functions are influenced by TB and warrants further research to confirm their potential as biomarkers for TB disease and treatment response. These results are further strengthened if the assumption holds that only 10 % of the ongoing immunologic response is represented in the peripheral blood when compared to the site of disease, namely the lungs. Further studies is thus needed to replicate this experiment on broncho-alveolar lavage (BAL) fluid from active TB diseased participants and other lung diseases to ascertain if the phenotype remains the same. Although the results from the BAL fluid experiment might give a better representation of the on-site B cell frequencies, the challenges associated with obtaining the bio fluid and characterisation of the (mostly activated) cells could hamper the process of finding biomarkers of disease or TB treatment response.
BAL, broncho alveolar lavage; COPD, chronic obstructive pulmonary disease; CS, class switched; IFN, interferon; M.tb, mycobacterium tuberculosis; NCS, non class switched; OLD, other lung diseases; PD-1, programmed death 1; TB, tuberculosis; TLR, toll like receptor
Special thank you to all the study participants and field staff of the Immunology Research Group (SUNIRG).
The financial assistance of the National Research Foundation (NRF) towards the research project of WJ du Plessis is hereby acknowledged. Opinions expressed and conclusions arrived at, are those of the authors and are not to be attributed to the NRF.
Availability of data and materials
All the data are presented in the manuscript. A spreadsheet of the data is attached as supporting document.
WJdP carried out the laboratory experiments. AK performed the flow cytometric analysis. AGL and GW planned the study. WJdP and AGL drafted the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
All participants gave written informed consent for partaking in the study after being briefed about the study’s aims and goals. The participants were also required to have their HIV status tested or declared to field workers. Samples were collected from two TB treatment studies. Ethical approval was obtained for both of these studies from the Health Research Ethics Committee of Stellenbosch University with ethics reference #: N10/01/013 and N13/05/064.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- WHO. Global Tuberculosis Report 2014 [Internet]. World Health Organization. 2014. Available from: http://reliefweb.int/report/world/global-tuberculosis-report-2014. Accessed 25 July 2016.
- Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1(6):475–82.View ArticlePubMedGoogle Scholar
- Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderón Gómez E, Sweenie CH, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol Baltim Md 1950. 2008;180(7):4763–73.Google Scholar
- Hoehlig K, Lampropoulou V, Roch T, Neves P, Calderon-Gomez E, Anderton SM, et al. Immune regulation by B cells and antibodies a view towards the clinic. Adv Immunol. 2008;98:1–38.View ArticlePubMedGoogle Scholar
- Neves P, Lampropoulou V, Calderon-Gomez E, Roch T, Stervbo U, Shen P, et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity. 2010;33(5):777–90.View ArticlePubMedGoogle Scholar
- du Plessis WJ, Kleynhans L, du Plessis N, Stanley K, Malherbe ST, Maasdorp E, et al. The functional response of B Cells to antigenic stimulation: a preliminary report of latent tuberculosis. PLoS One. 2016;11(4):e0152710.View ArticlePubMedPubMed CentralGoogle Scholar
- Hernandez J, Velazquez C, Valenzuela O, Robles-Zepeda R, Ruiz-Bustos E, Navarro M, et al. Low number of peripheral blood B lymphocytes in patients with pulmonary tuberculosis. Immunol Invest. 2010;39(3):197–205.View ArticlePubMedGoogle Scholar
- Wu YE, Zhang SW, Peng WG, Li KS, Li K, Jiang JK, et al. Changes in lymphocyte subsets in the peripheral blood of patients with active pulmonary tuberculosis. J Int Med Res. 2009;37(6):1742–9.View ArticlePubMedGoogle Scholar
- Hrušák O, Basso G, Ratei R, Gaipa G, Luria D, Mejstříková E, et al. Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping. Cytometry B Clin Cytom. 2014;86(4):288–91.View ArticlePubMedGoogle Scholar
- Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R, et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem. 1999;45(10):1708–17.PubMedGoogle Scholar
- Subasic D, Karamehic J, Delic-Sarac M, Kasumovic M, Mekic M, Eminovic I, et al. Monitoring of disease biomarkers activity and immunophenotyping as important factors in SLE clinical management. Med Arch Sarajevo Bosnia Herzeg. 2012;66(5):336–9.Google Scholar
- Boldt A, Borte S, Fricke S, Kentouche K, Emmrich F, Borte M, et al. Eight-color immunophenotyping of T-, B-, and NK-cell subpopulations for characterization of chronic immunodeficiencies. Cytom Part B - Clin Cytom. 2014;206(January):191–206.View ArticleGoogle Scholar
- Abreu MT, Carvalheiro H, Rodrigues-Sousa T, Domingos A, Segorbe-Luis A, Rodrigues-Santos P, Souto-Carneiro MM. Alterations in the peripheral blood B cell subpopulations of multidrug-resistant tuberculosis patients. Clin Exp Med. 2014;14(4):423-9. doi:10.1007/s10238-013-0258-1. Epub 2013 Sep 26. PubMed PMID: 24068613.
- Barcelos W, Martins-Filho OA, Guimarães TMPD, Oliveira MHP, Spíndola-de-Miranda S, Carvalho BN, et al. Peripheral blood mononuclear cells immunophenotyping in pulmonary tuberculosis patients before and after treatment. Microbiol Immunol. 2006;50(8):597–605.View ArticlePubMedGoogle Scholar
- Partnership A, Metropole C. TB control in Cape Town - progress report 1997–2003. 2003.Google Scholar
- Classen CN, Warren R, Richardson M, Hauman JH, Gie RP, Ellis JHP, et al. Impact of social interactions in the community on the transmission of tuberculosis in a high incidence area. Thorax. 1999;54(2):136–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Verver S, Warren RM, Munch Z, Vynnycky E, van Helden PD, Richardson M, et al. Transmission of tuberculosis in a high incidence urban community in South Africa. Int J Epidemiol. 2004;33(2):351–7.View ArticlePubMedGoogle Scholar
- Sebina I, Cliff JM, Smith SG, Nogaro S, Webb EL, Riley EM, et al. Long-lived memory B-cell responses following BCG vaccination. PLoS One. 2012;7(12):e51381.View ArticlePubMedPubMed CentralGoogle Scholar
- Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature. 1988;336(6194):70–3.View ArticlePubMedGoogle Scholar
- Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, et al. Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 2010;6(2):e1000770.View ArticlePubMedPubMed CentralGoogle Scholar
- Ward SM, Phalora P, Bradshaw D, Leyendeckers H, Klenerman P. Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. J Infect Dis. 2008;198(6):813–7.View ArticlePubMedGoogle Scholar
- Schittek B, Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. Nature. 1990;346(6286):749–51.View ArticlePubMedGoogle Scholar
- Singh A, Mohan A, Dey AB, Mitra DK. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. 2013;208(4):603–15.View ArticlePubMedGoogle Scholar